Abstract:This Review initiates a wide-ranging discussion over 2023 by selecting and exploring core themes to be investigated more deeply in papers submitted to the Vaccines Special Issue on the "Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs". To tackle the SARS-CoV-2 pandemic, an acceleration of vaccine development across different technology platforms resulted in the emergency use authorization of multiple vaccines in less than a year. Despite this record speed, many limitations surfaced including unequal access to products and technologies, regulatory hurdles, restrictions on the flow of intellectual property needed to develop and manufacture vaccines, clinical trials challenges, development of vaccines that did not curtail or prevent transmission, unsustainable strategies for dealing with variants, and the distorted allocation of funding to favour dominant companies in affluent countries. Key to future epidemic and pandemic responses will be sustainable, global-public-health-driven vaccine development and manufacturing based on equitable access to platform technologies, decentralised and localised innovation, and multiple developers and manufacturers, especially in low- and middle-income countries (LMICs). There is talk of flexible, modular pandemic preparedness, of technology access pools based on non-exclusive global licensing agreements in exchange for fair compensation, of WHO-supported vaccine technology transfer hubs and spokes, and of the creation of vaccine prototypes ready for phase I/II trials, etc. However, all these concepts face extraordinary challenges shaped by current commercial incentives, the unwillingness of pharmaceutical companies and governments to share intellectual property and know-how, the precariousness of building capacity based solely on COVID-19 vaccines, the focus on large-scale manufacturing capacity rather than small-scale rapid-response innovation to stop outbreaks when and where they occur, and the inability of many resource-limited countries to afford next-generation vaccines for their national vaccine programmes. Once the current high subsidies are gone and interest has waned, sustaining vaccine innovation and manufacturing capability in interpandemic periods will require equitable access to vaccine innovation and manufacturing capabilities in all regions of the world based on many vaccines, not just "pandemic vaccines". Public and philanthropic investments will need to leverage enforceable commitments to share vaccines and critical technology so that countries everywhere can establish and scale up vaccine development and manufacturing capability. This will only happen if we question all prior assumptions and learn the lessons offered by the current pandemic. We invite submissions to the special issue, which we hope will help guide the world towards a global vaccine research, development, and manufacturing ecosystem that better balances and integrates scientific, clinical trial, regulatory, and commercial interests and puts global public health needs first.

Antiscience, Vaccine Hesitancy, and Pandemic Responses: Highlights from the Asia Pacific Summit on Infectious Diseases and Immunization

3rd Global Vaccine Congress

ASVAC2022 : 8th Asian Vaccine Conference

ASVAC2019: 7th Asian Vaccine Conference

Quality vaccines for all people: Report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05-07th October 2015, Bangkok, Thailand

Vaccines, inspiring innovation in health

Expanding Research Capacity and Accelerating AIDS Vaccine Development in Asia.

Lessons learnt from COVID-19 to reduce mortality and morbidity in the Global South: addressing global vaccine equity for future pandemics

One world, one health: combating infectious diseases in the age of globalization

Progress in vaccine development for infectious diseases—a Keystone Symposia report

Addressing the re-emergence and resurgence of vaccine-preventable diseases in Africa: A health equity perspective

Strengthening Virology Research in the Association of Southeast Asian Nations: Preparing for Future Pandemics.

Innovative strategies to promote global health: Lessons from the Covid-19 pandemic

Sustainable Dengue Prevention and Management: Integrating Dengue Vaccination Strategies with Population Perspectives

Pandemic Response Lessons from Influenza H1N1 2009 in Asia

The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs

Pandemic response lessons from influenza H1N1 2009 in Asia.

Emerging respiratory infections threatening public health in the Asia-Pacific region: A position paper of the Asian Pacific Society of Respirology.

20th International Conference on Emerging Infectious Diseases in the Pacific Rim Organized by the United States-Japan Cooperative Medical Sciences Program (USJCMSP)

Report from the World Health Organization's Immunization and Vaccines-Related Implementation Research Advisory Committee (IVIR-AC) Meeting, Virtual Gathering, 10–13 September 2024

Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution